Pliant Therapeutics, Inc.

NasdaqGS:PLRX Rapport sur les actions

Capitalisation boursière : US$774.7m

Pliant Therapeutics Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Bernard Coulie

Directeur général

US$11.2m

Rémunération totale

Pourcentage du salaire du PDG5.5%
Durée du mandat du directeur général8.8yrs
Propriété du PDG1.1%
Durée moyenne d'occupation des postes de direction8.7yrs
Durée moyenne du mandat des membres du conseil d'administration7.1yrs

Mises à jour récentes de la gestion

Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Jun 07
Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Recent updates

Is Pliant Therapeutics (NASDAQ:PLRX) Using Too Much Debt?

Sep 13
Is Pliant Therapeutics (NASDAQ:PLRX) Using Too Much Debt?

Pliant Therapeutics: Good Data, But Will Need Watching

Sep 11

Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Jun 07
Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Feb 27
Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?

Jul 21
Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?

Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?

Mar 13
Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Sep 10
Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Pliant Therapeutics: Wait For A Better Price To Get In

Aug 20

Pliant Therapeutics GAAP EPS of -$0.82 misses by $0.01, revenue of $4.99M

Aug 08

Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?

Jul 28
Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?

Pliant's PLN-74809 gets FDA fast track status for liver disease

Jul 21

Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals

Jul 11

Pliant: Major Catalyst Expected Beginning Of 2023

Jun 03

We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate

Apr 22
We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate

Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation

Dec 29
Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation

We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth

Sep 07
We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth

Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%

May 17
Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

May 13
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans

Mar 22
Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans

Analyse de la rémunération des PDG

Comment la rémunération de Bernard Coulie a-t-elle évolué par rapport aux bénéfices de Pliant Therapeutics?
DateRémunération totaleSalaireBénéfices de l'entreprise
Sep 30 2024n/an/a

-US$202m

Jun 30 2024n/an/a

-US$185m

Mar 31 2024n/an/a

-US$171m

Dec 31 2023US$11mUS$610k

-US$161m

Sep 30 2023n/an/a

-US$155m

Jun 30 2023n/an/a

-US$144m

Mar 31 2023n/an/a

-US$133m

Dec 31 2022US$11mUS$587k

-US$123m

Sep 30 2022n/an/a

-US$113m

Jun 30 2022n/an/a

-US$109m

Mar 31 2022n/an/a

-US$103m

Dec 31 2021US$5mUS$556k

-US$97m

Sep 30 2021n/an/a

-US$92m

Jun 30 2021n/an/a

-US$81m

Mar 31 2021n/an/a

-US$75m

Dec 31 2020US$2mUS$499k

-US$42m

Sep 30 2020n/an/a

US$18m

Jun 30 2020n/an/a

US$19m

Mar 31 2020n/an/a

US$20m

Dec 31 2019US$2mUS$428k

-US$7m

Rémunération vs marché: La rémunération totale de Bernard ($USD 11.17M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 3.20M ).

Rémunération et revenus: La rémunération de Bernard a augmenté alors que l'entreprise n'est pas rentable.


PDG

Bernard Coulie (58 yo)

8.8yrs

Titularisation

US$11,165,999

Compensation

Dr. Bernard Coulie, Ph D, M.D. M.B.A. is Independent Director of Septerna, Inc. from December 2023. He serves as Independent Director at SQZ Biotechnologies Company since July 2021 and serves as its Indepe...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Bernard Coulie
Presidentno dataUS$11.17m1.1%
$ 8.5m
Keith Cummings
Chief Financial Officer5.9yrsUS$4.44m0.31%
$ 2.4m
Mike Ouimette
General Counsel & Corporate Secretary4.1yrsUS$3.32m0.060%
$ 465.2k
Johannes Hull
Chief Business Officer8.7yrsUS$4.36m0.32%
$ 2.4m
Eric Lefebvre
Chief Medical Officer6.5yrsUS$4.69m0.22%
$ 1.7m
Rik Derynck
Scientific Founder & Member of Scientific Advisory Board9.8yrspas de donnéespas de données
Dean Sheppard
Scientific Founder & Member of Scientific Advisory Board9.8yrspas de donnéespas de données
Bill DeGrado
Scientific Founder & Member of Scientific Advisory Board9.8yrspas de donnéespas de données
Hal Chapman
Scientific Founder & Member of Scientific Advisory Board9.8yrspas de donnéespas de données
Craig Muir
Interim Chief Technology Officerno datapas de donnéespas de données
Christopher Keenan
Vice President of Investor Relations & Corporate Communicationsno datapas de donnéespas de données
Lily Cheung
Chief Human Resources Officer1.8yrspas de données0.0013%
$ 10.1k

8.7yrs

Durée moyenne de l'emploi

51yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de PLRX est chevronnée et expérimentée (8.7 années d'ancienneté moyenne).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Bernard Coulie
President8.8yrsUS$11.17m1.1%
$ 8.5m
Rik Derynck
Scientific Founder & Member of Scientific Advisory Boardno datapas de donnéespas de données
Dean Sheppard
Scientific Founder & Member of Scientific Advisory Boardno datapas de donnéespas de données
Bill DeGrado
Scientific Founder & Member of Scientific Advisory Boardno datapas de donnéespas de données
Hal Chapman
Scientific Founder & Member of Scientific Advisory Boardno datapas de donnéespas de données
Gayle Crowell
Independent Director4.9yrsUS$278.71k0%
$ 0
Brian Metcalf
Member of Scientific Advisory Boardno datapas de donnéespas de données
Suzanne Bruhn
Independent Director8.3yrsUS$277.21k0.058%
$ 446.6k
John Curnutte
Independent Director7.3yrsUS$271.96k0.048%
$ 372.7k
Hoyoung Huh
Independent Chairman6.9yrsUS$296.71k0.16%
$ 1.3m
Smital Shah
Independent Director5.7yrsUS$277.96k0%
$ 0
Bill Greenlee
Member of Scientific Advisory Boardno datapas de donnéespas de données

7.1yrs

Durée moyenne de l'emploi

61yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de PLRX sont considérés comme expérimentés (ancienneté moyenne 7.1 ans).